GSK plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GLAXF research report →
Companywww.gsk.com
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology.
- CEO
- Luke Victor Miels
- IPO
- 2010
- Employees
- 68,629
- HQ
- Brentford, GB
Price Chart
Valuation
- Market Cap
- $102.55B
- P/E
- 13.10
- P/S
- 2.31
- P/B
- 4.28
- EV/EBITDA
- 7.90
- Div Yield
- 3.53%
Profitability
- Gross Margin
- 72.74%
- Op Margin
- 22.34%
- Net Margin
- 17.78%
- ROE
- 35.78%
- ROIC
- 13.76%
Growth & Income
- Revenue
- $32.66B · 4.10%
- Net Income
- $5.72B · 121.94%
- EPS
- $1.41 · 123.81%
- Op Income
- $7.17B
- FCF YoY
- 66.69%
Performance & Tape
- 52W High
- $31.48
- 52W Low
- $17.15
- 50D MA
- $27.04
- 200D MA
- $24.13
- Beta
- 0.30
- Avg Volume
- 1.14K
Get TickerSpark's AI analysis on GLAXF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our GLAXF Coverage
We haven't published any research on GLAXF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GLAXF Report →